Loading...
XLON
AVCT
Market cap461mUSD
Dec 05, Last price  
79.75GBP
1D
2.24%
1Q
39.91%
Jan 2017
10.76%
IPO
-92.68%
Name

Avacta Group PLC

Chart & Performance

D1W1MN
XLON:AVCT chart
P/E
—
P/S
3,060.59
EPS
—
Div Yield, %
—
Shrs. gr., 5y
22.12%
Rev. gr., 5y
-50.73%
Revenues
113k
-99.51%
313,0004,000212,000466,000944,0002,067,0002,445,0003,130,0002,700,0003,180,0001,813,0002,165,0002,735,0002,763,0003,890,1042,144,0002,941,0009,653,00023,247,000113,000
Net income
-53m
L+111.81%
-1,103,000-107,000-1,219,000-1,468,400-2,685,000-1,879,000-591,000-1,106,000-1,521,000-1,492,000-10,139,000-4,647,000-6,367,000-8,829,000-11,022,316-18,891,000-26,316,000-39,497,000-24,947,000-52,841,000
CFO
-24m
L+58.67%
-84,000-139,000-1,250,000-1,295,000-2,799,000-1,741,000-596,000-711,000-1,377,000-838,000-2,515,000-4,233,000-4,241,000-5,468,000-13,015,000-10,642,000-20,506,000-16,431,999-14,872,000-23,597,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
URL
https://avacta.com/
IPO date
Sep 08, 2003
Employees
120
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122019‑072018‑072017‑072016‑07
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT